SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0885 6222 "

Sökning: L773:0885 6222

  • Resultat 1-10 av 25
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Allgulander, C (författare)
  • Addiction on prescribed sedative-hypnotics
  • 1996
  • Ingår i: HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL. - 0885-6222. ; 11, s. S49-S54
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
3.
  •  
4.
  • Allgulander, Christer, et al. (författare)
  • Efficacy of venlafaxine ER in patients with social anxiety disorder : A double-blind, placebo-controlled, parallel-group comparison with paroxetine
  • 2004
  • Ingår i: Human Psychopharmacology. - : Wiley. - 0885-6222 .- 1099-1077. ; 19:6, s. 387-396
  • Tidskriftsartikel (refereegranskat)abstract
    • This study evaluated the anxiolytic efficacy, safety and tolerability of a flexible dose of venlafaxine extended release (ER) compared with placebo and paroxetine in the short-term treatment of generalized social anxiety disorder (SAD). Adult outpatients with generalized SAD (n=434) were randomized to receive capsules of venlafaxine ER 75 mg to 225 mg/day, paroxetine 20 mg to 50 mg/day, or placebo for 12 weeks. The primary efficacy variable was the Liebowitz social anxiety scale total score. Secondary efficacy variables included the patient-rated social phobia inventory and the proportion of responders in each group (a responder was defined as having a clinical global impression-improvement score of 1 or 2). Treatment with venlafaxine ER was associated with significantly greater improvement than treatment with placebo for all primary and secondary efficacy variables (p<0.05). No significant differences in primary or secondary efficacy variables were observed between the venlafaxine ER and paroxetine groups. The week 12 response rates were 69%, 66% and 36% for the venlafaxine ER, paroxetine and placebo groups, respectively. Both active treatments were generally well tolerated and were associated with a similar incidence of adverse events. This study shows that venlafaxine ER is an effective, safe and well-tolerated drug treatment for SAD.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  • Gunnarsson, Tove, 1956-, et al. (författare)
  • Cholecystokinin peptides in cerebrospinal fluid : a pilot study in hypothyroid patients
  • 1999
  • Ingår i: Human Psychopharmacology. - 0885-6222 .- 1099-1077. ; 14:2, s. 113-117
  • Tidskriftsartikel (refereegranskat)abstract
    • The cholecystokinin tetrapeptide (CCK-4) and the sulphated octapeptide (CCK-8) were measured in cerebrospinal fluid obtained from nine hypothyroid patients before and during L-thyroxine treatment. Before treatment, CCK-4 and CCK-8S correlated negatively with S-TSH, whereas CCK-8S also showed a positive correlation with S-T3. During treatment, S-T4 correlated negatively with CCK-8S. CSF collection time was significantly shorter during treatment than prior to treatment for the first (0–6 ml) CSF fraction. On taking CSF collection time into account, the levels of both CCK-4 and CCK-8S in the first CSF fraction were significantly increased during medication. Our results are consistent with an impact of the hypothyroid disorder and L-thyroxine treatment on the disposition of CCK compounds in CSF. This might be due to an altered CSF circulation, but other mechanisms (e.g. metabolism or elimination) cannot be ruled out.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 25

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy